The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma.

ABSTRACT: Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multiple myeloma (MM), but for older adults there is limited evidence on its effectiveness from clinical trials. We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to identify individuals age 66 years and older with multiple myeloma (MM) who were diagnosed between 2000 and 2007. We used traditional multivariable analysis, propensity score-based analysis, coarsened exact matching, and an instrumental variable analysis to compare survival for individuals who did or did not receive an hematopoietic stem cell transplant. Survival was measured by Cox proportional hazard models. All statistical tests were two-sided. Patients with MM receiving an HSCT were more likely to be w

SUBMITTER: Winn AN 

PROVIDER: S-EPMC4554189 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature